Search

Alan R Schenkel

from Fort Collins, CO
Age ~53
Get Report
Also known as:
Alan Rowe Schenkel, Alan R Schnekel
Phone and address:
1800 Manchester Dr, Fort Collins, CO 80526
(970) 482-2646
Related to:
Melissa A Schenkel, 31Sandra Christian, 77Jessica Rowe, 51Julia E Christian, 50Daniel Mccloy, 43
Connected to:
Aaron M Schenker, 33Albert F Schenkel, 72Allan J Schenkel, 48Anna N Schenker, 41Ashley B Schenker, 32Bill R Schenker, 84Charlotte P Schenken, 86Christian Schenker, 34Darren E Schenkel, 55David E Schenke, 30

Alan Schenkel Phones & Addresses

  • 1800 Manchester Dr, Fort Collins, CO 80526 (970) 482-2646 (970) 493-1853
  • 716 Tracey Pkwy, Fort Collins, CO 80524
  • Bosler, WY
  • 54 Hudson Heights Dr, Poughkeepsie, NY 12601 (845) 483-1137
  • 54 Stout Ct, Poughkeepsie, NY 12601 (845) 483-1137
  • Fitchburg, WI
  • Astoria, NY
  • Boulder, CO

Work

Position: Executive, Administrative, and Managerial

Education

Degree: Bachelor's degree or higher

Industries

Research

Resumes

Resumes

Alan Schenkel Photo 1

Alan Schenkel

View page
Location:
Fort Collins, Colorado Area
Industry:
Research

Publications

Us Patents

Blocking Leukocyte Emigration And Inflammation By Interfering With Cd99/Hec2

View page
US Patent:
20030211099, Nov 13, 2003
Filed:
Mar 27, 2003
Appl. No.:
10/221758
Inventors:
William Muller - Port Washington NY, US
Alan Schenkel - Poughkeepsie NY, US
International Classification:
A61K039/395
C07K016/28
US Classification:
424/144100, 530/388220
Abstract:
The present invention provides methods and compositions for modulating transendothelial migration (TEM) of leukocytes. In particular, inhibition of TEM can provide a potent therapeutic approach to treating inflammatory conditions. The invention specifically relates to the discovery that CD99 mediates TEM, because blocking CD99 on either endothelial cells or monocytes bloks migration 80-90%. In conjunction with PECAM inhibitors, TEM blockade approaches 100%. CD99 is involved in a step in TEM that is distal to the step controlled by PECAM.

System For Small Animal Aerosol Inhalation Chamber

View page
US Patent:
20090211534, Aug 27, 2009
Filed:
Feb 2, 2009
Appl. No.:
12/364493
Inventors:
Alan Rowe Schenkel - Fort Collins CO, US
William Glen Schroeder - Denver CO, US
John Volckens - Fort Collins CO, US
Assignee:
Alan Rowe Schenkel - For Collins CO
International Classification:
A01K 1/03
US Classification:
119420
Abstract:
This patent application is for an apparatus to safely expose guinea pigs and other small animals to biohazardous aerosol. It is composed of three main chambers housed in an outer box which fits within a conventionally sized biosafety cabinet. The animal chamber contains a removable housing unit for four or eight guinea pigs. The aerosol chamber is separate to minimize fur contamination. The nebulizer chamber is also sealed to reduce risks from leakages. This apparatus is easily decontaminated by immersion in disinfectant. The first version of the prototype, tentatively named the AXS1, has been tested for safety, ergonomics, efficiency of rodent exposure to bacteria, airflow, access points, seal mechanisms, and size.

Blocking Leukocyte Emigration And Inflammation By Interfering With Cd99L2

View page
US Patent:
20080213279, Sep 4, 2008
Filed:
Jun 30, 2006
Appl. No.:
11/994363
Inventors:
William A. Muller - Port Washimgton NY, US
Alan R. Schenkel - Ft. Collins CO, US
Assignee:
Cornell Research Foundation, Inc. - Ithaca
International Classification:
A61K 39/395
C12N 5/06
A61K 38/17
C07K 16/28
G01N 33/53
US Classification:
4241521, 4241721, 435375, 5303882, 5303873, 435 724
Abstract:
The present invention provides methods and compositions for modulating transendothelial migration (TEM) of leukocytes. In particular, inhibition of TEM can provide a potent therapeutic approach to treating inflammatory conditions. The invention specifically relates to the discovery that the adhesion molecule CD99L2 mediates TEM of leukocytes. CD99L2 is present on endothelial cells and leukocytes and mediates leukocyte-endothelial cell adhesion. Blockade of CD99L2 by use of a specific antibody blocks migration of leukocytes into a site of inflammation. CD99L2 shows functional analogy to the structurally-related molecule, CD99, inhibition of which, in conjunction with inhibition of PECAM, causes near total blockade of TEM. Thus, blocking CD99L2 on either endothelial cells or monocytes can block migration 80-90%. In conjunction with PECAM inhibitors, TEM blockade can approach 100%. Therapeutic treatments involving inhibition of CD99L2 show significant promise in remediation of inflammatory conditions.

Blocking Leukocyte Emigration And Inflammation By Interfering With Cd99/Hec2

View page
US Patent:
20070154450, Jul 5, 2007
Filed:
Feb 27, 2007
Appl. No.:
11/679683
Inventors:
William Muller - Port Washington NY, US
Alan Schenkel - Ft. Collins CO, US
International Classification:
A61K 38/20
A61K 38/19
A61K 38/17
A61K 39/395
US Classification:
424085100, 424144100, 424085200, 514012000
Abstract:
The present invention provides methods and compositions for modulating transendothelial migration (TEM) of leukocytes. In particular, inhibition of TEM can provide a potent therapeutic approach to treating inflammatory conditions. The invention specifically relates to the discovery that CD99 mediates TEM, because blocking CD99 on either endothelial cells or monocytes bloks migration 80-90%. In conjunction with PECAM inhibitors, TEM blockade approaches 100%. CD99 is involved in a step in TEM that is distal to the step controlled by PECAM.
Control profile
Alan R Schenkel from Fort Collins, CO, age ~53 Get Report